Pandemic H5N1 influenza virus vaccine - GlaxoSmithKline
Alternative Names: Flu mRNA - GSK; flu pandemic messenger RNA (mRNA) vaccine - GlaxoSmithKline; Flu Pandemic mRNA - GSK; H5N1 influenza vaccine - GlaxoSmithKline; H5N1 m-RNA vaccine - GlaxoSmithKlineLatest Information Update: 17 May 2024
At a glance
- Originator GSK
- Class Antivirals; Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Influenza virus infections
Most Recent Events
- 18 Apr 2024 Phase-I/II clinical trials in Influenza virus infections (Prevention, In volunteers) in USA (IM) (NCT06382311)